Curis, Inc. (CRIS)
-NasdaqGM 3.70 
0.18(4.64%) 04:00 SGT|After Hours
:
3.70 0.00 (0.00%) 04:31 SGT
| Prev Close: | 3.88 |
|---|
| Open: | 3.87 |
|---|
| Bid: | 3.07 x 100 |
|---|
| Ask: | 3.96 x 1400 |
|---|
| 1y Target Est: | 6.86 |
|---|
| Beta: | 2.1 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 3.70 - 3.97 |
|---|
| 52wk Range: | 2.66 - 5.51 |
|---|
| Volume: | 671,582 |
|---|
| Avg Vol (3m): | 575,657 |
|---|
| Market Cap: | 297.99M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.30 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Curis to Present at the Deutsche Bank 38th Annual dbAccess Health Care ConferenceGlobeNewswire(Wed, 22 May)
- American Society Of Clinical Oncology Abstracts Point To Potential Profitsat Seeking Alpha(Tue, 21 May)
- CURIS INC FinancialsEDGAR Online Financials(Sat, 18 May)
- Curis Announces Presentation of CUDC-427 and Erivedge(R) Clinical Results at ASCO Annual MeetingGlobeNewswire(Thu, 16 May)
- 10 ASCO '13 Abstracts You Can Read Right Nowat TheStreet(Thu, 16 May)
- Three of WellPoint's directors resign for personal reasonsat Reuters(Tue, 14 May)
- Curis Announces Approval of Erivedge(R) in AustraliaGlobeNewswire(Fri, 10 May)
- CURIS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, 9 May)
- Incremental Changes in Regulatory Environment Beneficial to Development-Stage Biotech Companies Due to Emphasis on Closer Working Relationships with the FDA and Drug SponsorsWall Street Transcript(Wed, 1 May)
- EU body backs new Roche, Astellas, Sanofi, Vivus drugsReuters(Fri, 26 Apr)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 41.74 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.22 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.02 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Curis, Inc. engages in the research, development, and commercialization of cancer therapeutics. Its principal product is Erivedge capsule for treatment of adults with basal cell carcinoma (BCC) that has spread to other parts of the body or that ha...
View More